INT32203

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1983
Last Reported 2010
Negated 0
Speculated 3
Reported most in Abstract
Documents 48
Total Number 51
Disease Relevance 32.77
Pain Relevance 11.89

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Crp) extracellular region (Crp)
Anatomy Link Frequency
erythrocyte 6
blood 3
plasma 1
urine 1
joint 1
Crp (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Inflammation 125 100.00 Very High Very High Very High
Inflammatory marker 43 100.00 Very High Very High Very High
cytokine 11 100.00 Very High Very High Very High
anesthesia 4 100.00 Very High Very High Very High
aspirin 192 99.70 Very High Very High Very High
backache 6 99.48 Very High Very High Very High
carbamazepine 11 99.46 Very High Very High Very High
dexamethasone 3 99.40 Very High Very High Very High
Pain 33 99.38 Very High Very High Very High
cINOD 16 98.94 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 189 100.00 Very High Very High Very High
Disease 54 100.00 Very High Very High Very High
Obesity 42 100.00 Very High Very High Very High
Adhesions 10 100.00 Very High Very High Very High
Hyperlipidemia 7 99.80 Very High Very High Very High
Nicotine Addiction 122 99.56 Very High Very High Very High
Coronary Artery Disease 117 99.56 Very High Very High Very High
Hypertension 117 99.56 Very High Very High Very High
Cardiovascular Disease 44 99.52 Very High Very High Very High
Low Back Pain 11 99.48 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Clinical improvement was associated with the reduction of acute phase reactants, such as C-reactive protein levels.
Negative_regulation (reduction) of C-reactive protein
1) Confidence 0.58 Published 2010 Journal Joint Bone Spine Section Body Doc Link 20452801 Disease Relevance 0 Pain Relevance 0
Patients treated with remission-inducing drugs (RIDs) had improved clinical measurements and also reduced erythrocyte sedimentation rate and serum C-reactive protein levels.
Negative_regulation (reduced) of C-reactive protein in erythrocyte
2) Confidence 0.58 Published 1983 Journal Scand. J. Rheumatol. Section Abstract Doc Link 6623019 Disease Relevance 0.42 Pain Relevance 0.25
Compared with controls, dexamethasone-eluting stents significantly reduced C-reactive protein peak levels 48 hours after the procedure; this effect persisted for 7 days and was particularly evident in patients with elevated (>/=3 mg/L) preprocedural C-reactive protein values.
Negative_regulation (reduced) of C-reactive protein associated with dexamethasone
3) Confidence 0.58 Published 2005 Journal Am. J. Cardiol. Section Abstract Doc Link 15695139 Disease Relevance 0.68 Pain Relevance 0.55
Reinforcing this finding, a significant reduction in inflammatory laboratory parameters, erythrocyte sedimentation rate (24.7 +/- 15.5 vs 12.8 +/- 10.8 mm/h; p = 0.036) and C-reactive protein (24.0 +/- 14.9 vs 11.2 +/- 10.7 mg/l; p = 0.0167), was observed.
Negative_regulation (reduction) of C-reactive protein in erythrocyte associated with inflammation
4) Confidence 0.58 Published 2007 Journal Clin. Rheumatol. Section Abstract Doc Link 17332971 Disease Relevance 1.12 Pain Relevance 0.21
Significant improvement in the joint complaints and inflammation parameters was observed including a decrease in the number of painful (-46%) and swollen (-45%) joints, tenderness (Ritchie Index: -50%) and degree of swelling (-46%), patient's assessment of pain (-35%), the duration of morning joint stiffness (-37%), as well as a decrease in C-reactive protein (-52%).
Negative_regulation (decrease) of C-reactive protein in joint associated with pain, pressure and volume under development and inflammation
5) Confidence 0.58 Published 1996 Journal Br. J. Dermatol. Section Abstract Doc Link 8977676 Disease Relevance 0.76 Pain Relevance 0.38
Two months later, the C-reactive protein level had decreased from 2.3 mg/dL to 1.1 mg/dL, and both the focal wall thickening and (18)FDG uptake of the thoracic aorta were decreased. 18FDG PET was useful for evaluating the efficacy of the steroid therapy in addition to making a diagnosis of Takayasu's arteritis associated with antiphospholipid syndrome.
Negative_regulation (decreased) of C-reactive protein in thickening associated with anti-phospholipid antibody syndrome and increased venous pressure under development
6) Confidence 0.58 Published 2006 Journal International heart journal Section Abstract Doc Link 16607057 Disease Relevance 0.72 Pain Relevance 0.14
Treatment with simvastatin (5 mg/day) did not reverse renal failure and hypereosinophilia, but the amputation of right gangrene toes promptly increased urine output and eosinophilia completely disappeared concomitantly with a decline of C-reactive protein from 9.7 to 0.7 mg/dl.
Negative_regulation (decline) of C-reactive protein in urine associated with renal failure, amputation, increased venous pressure under development and eosinophilia
7) Confidence 0.49 Published 2002 Journal Nephron Section Abstract Doc Link 12187114 Disease Relevance 1.18 Pain Relevance 0.23
Levels of high-sensitivity C-reactive protein decreased after treatment with antispastic agents.
Negative_regulation (decreased) of C-reactive protein
8) Confidence 0.42 Published 2005 Journal Am. J. Cardiol. Section Abstract Doc Link 15619396 Disease Relevance 0.15 Pain Relevance 0.26
Forty-eight hours after randomization, mean C-reactive protein levels decreased by 2.6 mg. l(-1)in the methylprednisolone group, but increased by 1.6 mg. l(-1)in the placebo group (P=0.03).
Negative_regulation (decreased) of C-reactive protein
9) Confidence 0.42 Published 2000 Journal Eur. Heart J. Section Body Doc Link 11102253 Disease Relevance 0.14 Pain Relevance 0
Long-term treatment with nifedipine (nifedipine CR, 20 mg/day for 4 months) decreased levels of C-reactive protein in the coronary sinus (from 0.35 +/- 0.09 mg/dl to 0.07 +/- 0.01 mg/dl, mean +/- SEM, p <0.05) and enhanced acetylcholine-induced increases in coronary blood flow.
Negative_regulation (decreased) of C-reactive protein in blood
10) Confidence 0.42 Published 2005 Journal Am. J. Cardiol. Section Abstract Doc Link 15877999 Disease Relevance 0.26 Pain Relevance 0.26
We assessed whether differences exist in C-reactive protein levels and their prognostic value in men compared with women.
Spec (whether) Negative_regulation (exist) of C-reactive protein
11) Confidence 0.42 Published 2000 Journal Eur. Heart J. Section Abstract Doc Link 10988012 Disease Relevance 0.27 Pain Relevance 0.07
Cilostazol increased high-density lipoprotein-cholesterol level, maximal walking distance, and FBF(h), whereas pentoxifylline reduced C-reactive protein level and increased maximal walking distance in total and nonsmoking groups.
Negative_regulation (reduced) of C-reactive protein
12) Confidence 0.41 Published 2008 Journal Angiology Section Abstract Doc Link 18388031 Disease Relevance 0.86 Pain Relevance 0.35
The lumbar back pain improved and there was a decrease in C-reactive protein to the normal range 3 weeks after onset.
Negative_regulation (decrease) of C-reactive protein associated with backache
13) Confidence 0.41 Published 2002 Journal Clin. Orthop. Relat. Res. Section Abstract Doc Link 12360015 Disease Relevance 0.66 Pain Relevance 0.24
This review focuses on the importance of high-sensitivity C-reactive protein in cardiovascular risk stratification in coronary heart disease patients and discusses several preventive therapies that may reduce cardiovascular risk through reduction in high-sensitivity C-reactive protein.
Negative_regulation (reduction) of C-reactive protein in heart associated with coronary artery disease
14) Confidence 0.37 Published 2002 Journal Curr. Opin. Cardiol. Section Abstract Doc Link 12151864 Disease Relevance 0.81 Pain Relevance 0.19
Laboratory analyses included determination of C-reactive protein, fibrinogen, D-dimer, HDL-cholesterol, LDL-cholesterol and triglycerides.
Negative_regulation (determination) of C-reactive protein
15) Confidence 0.32 Published 2000 Journal Eur. Heart J. Section Body Doc Link 10901512 Disease Relevance 0.21 Pain Relevance 0
For example, in 34 PWEs taking two of the most frequently prescribed enzyme-inducing AEDs (phenytoin and carbamazepine), hyperlipidemia and high C-reactive protein decreased significantly when switched to AEDs without enzyme-inducing properties (lamotrigine and levetiracetam) [11].
Negative_regulation (decreased) of C-reactive protein associated with epilepsy, lamotrigine, hyperlipidemia, antiepileptic drug and carbamazepine
16) Confidence 0.27 Published 2010 Journal F1000 Med Rep Section Body Doc Link PMC2990413 Disease Relevance 0.61 Pain Relevance 0.44
High-sensitivity C-reactive protein was reduced only in the atorvastatin arms (as previously recorded in other populations), and no change was seen accompanying TMI reduction with amlodipine.20 This clearly does not imply a causal role for C-reactive protein in the pathogenesis of TMI or angina.
Negative_regulation (reduced) of C-reactive protein in arms associated with coronary artery disease and cva
17) Confidence 0.27 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2966969 Disease Relevance 1.06 Pain Relevance 0.14
In the patients who received atorvastatin, a reduction in TMI was accompanied by a decrease in high-sensitivity C-reactive protein [median ?
Negative_regulation (decrease) of C-reactive protein associated with coronary artery disease
18) Confidence 0.27 Published 2010 Journal European Heart Journal Section Body Doc Link PMC2966969 Disease Relevance 0.41 Pain Relevance 0
Both treatment groups experienced a significant reduction in all measures of obesity, glucose metabolism, blood pressure, total and low-density lipoprotein cholesterol, triglycerides and C-reactive protein during follow-up (all P?
Negative_regulation (reduction) of C-reactive protein in blood associated with obesity
19) Confidence 0.25 Published 2010 Journal European Journal of Endocrinology Section Body Doc Link PMC2950661 Disease Relevance 0.63 Pain Relevance 0.04
A decreasing trend of C-reactive protein, a marker for inflammation, was also observed in those subjects who presented with elevated C-reactive protein.
Negative_regulation (decreasing) of C-reactive protein associated with inflammation
20) Confidence 0.23 Published 2005 Journal Phytother Res Section Abstract Doc Link 16261517 Disease Relevance 1.23 Pain Relevance 0.77

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox